Mesoblast (NASDAQ:MESO) received a $14.00 price target from research analysts at Maxim Group in a note issued to investors on Wednesday, March 7th. The firm currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 111.48% from the company’s previous close.
MESO has been the topic of several other reports. Zacks Investment Research lowered shares of Mesoblast from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 16th. Oppenheimer set a $16.00 price objective on shares of Mesoblast and gave the stock a “buy” rating in a report on Tuesday, November 14th. Finally, Cantor Fitzgerald set a $23.00 price target on shares of Mesoblast and gave the company a “buy” rating in a report on Wednesday, February 21st. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $13.54.
Mesoblast (NASDAQ:MESO) traded up $0.20 during midday trading on Wednesday, reaching $6.62. 36,876 shares of the company’s stock traded hands, compared to its average volume of 66,836. The firm has a market cap of $631.89, a price-to-earnings ratio of -17.35 and a beta of 1.83. Mesoblast has a 52 week low of $4.74 and a 52 week high of $12.50.
An institutional investor recently bought a new position in Mesoblast stock. Princeton Capital Management LLC acquired a new stake in shares of Mesoblast limited (NASDAQ:MESO) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 124,022 shares of the company’s stock, valued at approximately $724,000. Princeton Capital Management LLC owned 0.13% of Mesoblast as of its most recent filing with the Securities & Exchange Commission. 3.00% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Mesoblast (MESO) Given a $14.00 Price Target at Maxim Group” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/03/14/mesoblast-meso-given-a-14-00-price-target-at-maxim-group.html.
Mesoblast Company Profile
Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.